Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03386513 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

StatusActive, Not Recruiting
PhasePhase 1/2
SponsorAbbVie
Started2018-01-02
View on ClinicalTrials.gov ↗
This is an open-label, multi-center, Phase 1/2 study to determine the MTD and assess the safety, tolerability, PK, immunogenicity, and anti-leukemia activity of IMGN632 when administered as monotherapy to patients with CD123+ disease.

Amendment history 3 changes detected by DataLookout

2026-09-05
Primary endpoint(s) modified
WasTo assess the rate of composite CR in BPDCN patients
NowComposite Complete Remission/Response (CCR) Rate As Assessed by Investigator in Frontline De Novo Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Participants
2026-09-05
Primary completion pushed: 2023-09-06 → 2024-10-02
2026-09-05
Results posted: 2026-09-04
Trial Details
NCT Number NCT03386513
Lead Sponsor AbbVie
Conditions Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
Enrollment 179 participants
Start Date 2018-01-02
Primary Completion 2024-10-02 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-09-04